Suppr超能文献

血浆D-二聚体在卵巢癌中的临床意义:一项荟萃分析。

Clinical significance of plasma D-dimer in ovarian cancer: A meta-analysis.

作者信息

Wu Jiacong, Fu Ziyi, Liu Guangquan, Xu Pengfei, Xu Juan, Jia Xuemei

机构信息

Nantong Maternity and Child Health Care Hospital, Nantong Nanjing Maternity and Child Health Medical Institute, Nanjing Maternity and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing Department of Obstetrics and Gynecology, Nanjing Maternity and Child Health Care Hospital, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University, Nanjing, China.

出版信息

Medicine (Baltimore). 2017 Jun;96(25):e7062. doi: 10.1097/MD.0000000000007062.

Abstract

BACKGROUND

D-dimer has been widely used for the diagnosis and prognosis of ovarian cancer, but there is still controversy on its prediction value of ovarian cancer.

OBJECTIVES

To explore the clinical significance of plasma D-dimer level on ovarian cancer systematically.

METHODS

Using PubMed, Cochrane Library, and Web of Science libraries, all the relevant studies for the diagnostic and prognostic value of plasma D-dimer for ovarian cancer and the relationship between elevated D-dimer level and venous thromboembolism (VTE) risk of ovarian cancer were searched till May 30, 2016. Standardized mean difference (SMD), odds ratio (OR), hazard ratio (HR), and 95% confidence interval (CI) were appropriately pooled.

RESULTS

A total of 15 eligible studies involving a total of 1437 cancer patients were included. No significant association was found between high D-dimer level and overall survival of patients with ovarian cancer (HR 1.32, 95% CI: 0.90-1.95, P  =  .044). However, subgroup analysis indicated that the sample sizes could explain the heterogeneity between studies. And elevated D-dimer could predict increased risk of mortality when the sample sizes were >100 (HR 1.800, 95% CI: 1.283-2.523, P  =  .845). Besides, plasma D-dimer level was significantly higher in malignant ovarian cancer patients compared with benign controls (SMD 0.774, 95% CI: 0.597-0.951, P  =  .39), higher in advanced ovarian cancer patients (International Federation of Gynecology and Obstetrics [FIGO] classification III and IV) than in early stage ovarian cancer patients (FIGO classification I and II, SMD 0.611, 95% CI: 0.373-0.849, P  =  .442). And high D-dimer level indicated high VTE risk (OR 4.068, 95% CI: 2.423-6.829, P  =  .629) of ovarian cancer patients.

CONCLUSION

The plasma D-dimer level in ovarian cancer patients can predict the changes that correlated with disease progression and the VTE risk. But its predictive value for the prognosis of ovarian cancer was significantly dependent on the sample sizes. More well-designed studies with large sample sizes are needed to validate and update the findings of present study.

摘要

背景

D-二聚体已广泛应用于卵巢癌的诊断和预后评估,但关于其对卵巢癌的预测价值仍存在争议。

目的

系统探讨血浆D-二聚体水平在卵巢癌中的临床意义。

方法

利用PubMed、Cochrane图书馆和Web of Science数据库,检索截至2016年5月30日所有关于血浆D-二聚体对卵巢癌诊断和预后价值以及D-二聚体水平升高与卵巢癌静脉血栓栓塞(VTE)风险之间关系的相关研究。对标准化均数差(SMD)、比值比(OR)、风险比(HR)及95%置信区间(CI)进行适当合并。

结果

共纳入15项符合条件的研究,涉及1437例癌症患者。未发现高D-二聚体水平与卵巢癌患者总生存期之间存在显著关联(HR 1.32,95% CI:0.90 - 1.95,P = 0.044)。然而,亚组分析表明样本量可解释研究间的异质性。当样本量>100时,D-二聚体升高可预测死亡风险增加(HR 1.800,95% CI:1.283 - 2.523,P = 0.845)。此外,恶性卵巢癌患者血浆D-二聚体水平显著高于良性对照组(SMD 0.774,95% CI:0.597 - 0.951,P = 0.39),晚期卵巢癌患者(国际妇产科联盟[FIGO]分期III和IV期)高于早期卵巢癌患者(FIGO分期I和II期,SMD 0.611,95% CI:0.373 - 0.849,P = 0.442)。高D-二聚体水平表明卵巢癌患者VTE风险高(OR 4.068,95% CI:2.423 - 6.829,P = 0.629)。

结论

卵巢癌患者血浆D-二聚体水平可预测与疾病进展及VTE风险相关的变化。但其对卵巢癌预后的预测价值显著依赖于样本量。需要更多设计良好的大样本研究来验证和更新本研究结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f04/5484191/864ecbc58940/medi-96-e7062-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验